UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform

PloS one, 2013-10, Vol.8 (10), p.e75518-e75518

2013

Link zum Volltext

Verfügbarkeit prüfen

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

Nature (London), 2002-04, Vol.416 (6881), p.603-607

2002

Link zum Volltext

Verfügbarkeit prüfen

Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death

PloS one, 2011-03, Vol.6 (3), p.e17659

2011

Link zum Volltext

Verfügbarkeit prüfen

Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins

PloS one, 2014-05, Vol.9 (5), p.e94972-e94972

2014

Link zum Volltext

Verfügbarkeit prüfen

Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma

Journal of allergy and clinical immunology, 2023-04, Vol.151 (4), p.966-975

2023

Link zum Volltext

Verfügbarkeit prüfen

Sustained plasma hepcidin suppression and iron elevation by Anticalin‐derived hepcidin antagonist in cynomolgus monkey

British journal of pharmacology, 2018-04, Vol.175 (7), p.1054-1065

2018

Link zum Volltext

Verfügbarkeit prüfen

Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class

Angiogenesis (London), 2016-01, Vol.19 (1), p.79-94

2016

Link zum Volltext

Verfügbarkeit prüfen

Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

The Journal of experimental medicine, 2000-04, Vol.191 (7), p.1209-1220

2000

Link zum Volltext

Verfügbarkeit prüfen

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity

Molecular cancer therapeutics, 2013-11, Vol.12 (11), p.2459-2471

2013

Link zum Volltext

Verfügbarkeit prüfen

Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors

The Journal of immunology (1950), 2001-12, Vol.167 (11), p.6217-6224

2001

Link zum Volltext

Verfügbarkeit prüfen

Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin

Clinical chemistry (Baltimore, Md.), 2014-06, Vol.60 (6), p.897-899

2014

Link zum Volltext

Verfügbarkeit prüfen

CD95 (Fas) Ligand-Expressing Vesicles Display Antibody-Mediated, FcR-Dependent Enhancement of Cytotoxicity

The Journal of immunology (1950), 2000-11, Vol.165 (10), p.5487-5494

2000

Link zum Volltext

Verfügbarkeit prüfen

Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Expert review of clinical immunology, 2007-07, Vol.3 (4), p.491-501

2007

Link zum Volltext

Verfügbarkeit prüfen

Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells

The Journal of immunology (1950), 2004-06, Vol.172 (11), p.6598-6606

2004

Link zum Volltext

Verfügbarkeit prüfen

Fas-Ligand—Iron Fist or Achilles' Heel?

Clinical Immunology, 2002-04, Vol.103 (1), p.1-6

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3875: Exploiting the Anticalin therapeutic protein platform for the treatment of cMet ligand-independent and dependent tumors - discovery and characterization of a highly specific and potent c-Met antagonist with drug-like properties

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3875-3875

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations

Blood, 2011-11, Vol.118 (21), p.687-687

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3632: Nonclinical pharmacokinetics and safety of Angiocal, the first VEGF-A-specific alternative scaffold protein entering clinical development for cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3632-3632

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3621: A monovalent Anticalin antagonist: A novel approach for inhibition of c-Met-dependent tumor growth

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3621-3621

2011

Link zum Volltext

Verfügbarkeit prüfen

Anticalins super( registered ): the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Expert review of clinical immunology, 2007-07, Vol.3 (4), p.491-501

2007

Link zum Volltext

Verfügbarkeit prüfen

Multimodality Multiparametric Imaging of Early Tumor Response to a Novel Antiangiogenic Therapy Based on Anticalins: e94972

PloS one, 2014-05, Vol.9 (5)

2014

Link zum Volltext

Verfügbarkeit prüfen

Structure and expression of a non-polyadenylated ribosome bound transcript carrying the sequence of human ribosomal protein L7 mRNA in antisense orientation

Biological chemistry, 1998-08, Vol.379 (8-9), p.1193-1200

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Plos One
(4)
Cancer Research
(3)
The Journal Of Immunology
(3)
Expert Review Of Clinical Immunology
(2)
Angiogenesis
(1)
Biological Chemistry
(1)
Blood
(1)
British Journal Of Pharmacology
(1)
Clinical Chemistry
(1)
Clinical Immunology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death

Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins

Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma

Sustained plasma hepcidin suppression and iron elevation by Anticalin‐derived hepcidin antagonist in cynomolgus monkey

Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class

BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics

Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity

Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors

Engineered human lipocalin as an antibody mimetic: application to analysis of the small peptide hormone hepcidin

CD95 (Fas) Ligand-Expressing Vesicles Display Antibody-Mediated, FcR-Dependent Enhancement of Cytotoxicity

Anticalins®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells

Fas-Ligand—Iron Fist or Achilles' Heel?

Abstract 3875: Exploiting the Anticalin therapeutic protein platform for the treatment of cMet ligand-independent and dependent tumors - discovery and characterization of a highly specific and potent c-Met antagonist with drug-like properties

Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations

Abstract 3632: Nonclinical pharmacokinetics and safety of Angiocal, the first VEGF-A-specific alternative scaffold protein entering clinical development for cancer

Abstract 3621: A monovalent Anticalin antagonist: A novel approach for inhibition of c-Met-dependent tumor growth

Anticalins super( registered ): the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

Multimodality Multiparametric Imaging of Early Tumor Response to a Novel Antiangiogenic Therapy Based on Anticalins: e94972

Structure and expression of a non-polyadenylated ribosome bound transcript carrying the sequence of human ribosomal protein L7 mRNA in antisense orientation

Suchergebnisse filtern